PortalPublikationenBoswellia serrata extract for the treatment of collagenous c...

Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial

Standard

Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. / Madisch, Ahmed; Miehlke, Stephan; Eichele, Otto; Mrwa, Jenny; Bethke, Birgit; Kuhlisch, Eberhard; Bästlein, Elke; Wilhelms, Georg; Morgner, Andrea; Wigginghaus, Bernd; Stolte, Manfred.

in: INT J COLORECTAL DIS, Jahrgang 22, Nr. 12, 12.2007, S. 1445-51.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Madisch, A, Miehlke, S, Eichele, O, Mrwa, J, Bethke, B, Kuhlisch, E, Bästlein, E, Wilhelms, G, Morgner, A, Wigginghaus, B & Stolte, M 2007, 'Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial', INT J COLORECTAL DIS, Jg. 22, Nr. 12, S. 1445-51. https://doi.org/10.1007/s00384-007-0364-1

APA

Madisch, A., Miehlke, S., Eichele, O., Mrwa, J., Bethke, B., Kuhlisch, E., Bästlein, E., Wilhelms, G., Morgner, A., Wigginghaus, B., & Stolte, M. (2007). Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. INT J COLORECTAL DIS, 22(12), 1445-51. https://doi.org/10.1007/s00384-007-0364-1

Vancouver

Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. INT J COLORECTAL DIS. 2007 Dez;22(12):1445-51. https://doi.org/10.1007/s00384-007-0364-1

Bibtex

@article{54f1414afb1c4263a72e360d5c352c43,
title = "Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial",
abstract = "BACKGROUND AND AIMS: The objective of this study was to investigate the effect of Boswellia serrata extract (BSE) on symptoms, quality of life, and histology in patients with collagenous colitis.MATERIALS AND METHODS: Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral BSE 400 mg three times daily for 6 weeks or placebo. Complete colonoscopy and histology were performed before and after treatment. Clinical symptoms and quality of life were assessed by standardized questionnaires and SF-36. The primary endpoint was the percentage of patients with clinical remission after 6 weeks (stool frequencyRESULTS: Thirty-one patients were randomized; 26 patients were available for per-protocol-analysis. After 6 weeks, the proportion of patients in clinical remission was higher in the BSE group than in the placebo group (per protocol 63.6%; 95%CI, 30.8-89.1 vs 26.7%, 95%CI, 7.7-55.1; p=0.04; intention-to-treat 43.8% vs 26.7%, p=0.25). Compared to placebo, BSE treatment had no effect on histology and quality of life. Five patients discontinued BSE treatment prematurely. Discontinuation was due to adverse events (n=1), unwillingness to continue (n=3), or loss to follow-up for unknown reasons (n=1). Seven patients received open-label BSE therapy, five of whom achieved complete remission.CONCLUSIONS: Our study suggests that BSE might be clinically effective in patients with collagenous colitis. Larger trials are clearly necessary to establish the clinical efficacy of BSE.",
keywords = "Administration, Oral, Aged, Anti-Inflammatory Agents, Boswellia, Chronic Disease, Colitis, Collagenous, Colon, Diarrhea, Double-Blind Method, Female, Gastrointestinal Agents, Germany, Humans, Male, Middle Aged, Patient Compliance, Plant Extracts, Quality of Life, Surveys and Questionnaires, Time Factors, Treatment Outcome, Journal Article, Multicenter Study, Randomized Controlled Trial",
author = "Ahmed Madisch and Stephan Miehlke and Otto Eichele and Jenny Mrwa and Birgit Bethke and Eberhard Kuhlisch and Elke B{\"a}stlein and Georg Wilhelms and Andrea Morgner and Bernd Wigginghaus and Manfred Stolte",
year = "2007",
month = dec,
doi = "10.1007/s00384-007-0364-1",
language = "English",
volume = "22",
pages = "1445--51",
journal = "INT J COLORECTAL DIS",
issn = "0179-1958",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial

AU - Madisch, Ahmed

AU - Miehlke, Stephan

AU - Eichele, Otto

AU - Mrwa, Jenny

AU - Bethke, Birgit

AU - Kuhlisch, Eberhard

AU - Bästlein, Elke

AU - Wilhelms, Georg

AU - Morgner, Andrea

AU - Wigginghaus, Bernd

AU - Stolte, Manfred

PY - 2007/12

Y1 - 2007/12

N2 - BACKGROUND AND AIMS: The objective of this study was to investigate the effect of Boswellia serrata extract (BSE) on symptoms, quality of life, and histology in patients with collagenous colitis.MATERIALS AND METHODS: Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral BSE 400 mg three times daily for 6 weeks or placebo. Complete colonoscopy and histology were performed before and after treatment. Clinical symptoms and quality of life were assessed by standardized questionnaires and SF-36. The primary endpoint was the percentage of patients with clinical remission after 6 weeks (stool frequencyRESULTS: Thirty-one patients were randomized; 26 patients were available for per-protocol-analysis. After 6 weeks, the proportion of patients in clinical remission was higher in the BSE group than in the placebo group (per protocol 63.6%; 95%CI, 30.8-89.1 vs 26.7%, 95%CI, 7.7-55.1; p=0.04; intention-to-treat 43.8% vs 26.7%, p=0.25). Compared to placebo, BSE treatment had no effect on histology and quality of life. Five patients discontinued BSE treatment prematurely. Discontinuation was due to adverse events (n=1), unwillingness to continue (n=3), or loss to follow-up for unknown reasons (n=1). Seven patients received open-label BSE therapy, five of whom achieved complete remission.CONCLUSIONS: Our study suggests that BSE might be clinically effective in patients with collagenous colitis. Larger trials are clearly necessary to establish the clinical efficacy of BSE.

AB - BACKGROUND AND AIMS: The objective of this study was to investigate the effect of Boswellia serrata extract (BSE) on symptoms, quality of life, and histology in patients with collagenous colitis.MATERIALS AND METHODS: Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral BSE 400 mg three times daily for 6 weeks or placebo. Complete colonoscopy and histology were performed before and after treatment. Clinical symptoms and quality of life were assessed by standardized questionnaires and SF-36. The primary endpoint was the percentage of patients with clinical remission after 6 weeks (stool frequencyRESULTS: Thirty-one patients were randomized; 26 patients were available for per-protocol-analysis. After 6 weeks, the proportion of patients in clinical remission was higher in the BSE group than in the placebo group (per protocol 63.6%; 95%CI, 30.8-89.1 vs 26.7%, 95%CI, 7.7-55.1; p=0.04; intention-to-treat 43.8% vs 26.7%, p=0.25). Compared to placebo, BSE treatment had no effect on histology and quality of life. Five patients discontinued BSE treatment prematurely. Discontinuation was due to adverse events (n=1), unwillingness to continue (n=3), or loss to follow-up for unknown reasons (n=1). Seven patients received open-label BSE therapy, five of whom achieved complete remission.CONCLUSIONS: Our study suggests that BSE might be clinically effective in patients with collagenous colitis. Larger trials are clearly necessary to establish the clinical efficacy of BSE.

KW - Administration, Oral

KW - Aged

KW - Anti-Inflammatory Agents

KW - Boswellia

KW - Chronic Disease

KW - Colitis, Collagenous

KW - Colon

KW - Diarrhea

KW - Double-Blind Method

KW - Female

KW - Gastrointestinal Agents

KW - Germany

KW - Humans

KW - Male

KW - Middle Aged

KW - Patient Compliance

KW - Plant Extracts

KW - Quality of Life

KW - Surveys and Questionnaires

KW - Time Factors

KW - Treatment Outcome

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

U2 - 10.1007/s00384-007-0364-1

DO - 10.1007/s00384-007-0364-1

M3 - SCORING: Journal article

C2 - 17764013

VL - 22

SP - 1445

EP - 1451

JO - INT J COLORECTAL DIS

JF - INT J COLORECTAL DIS

SN - 0179-1958

IS - 12

ER -